In the phase 2 clinical trial pembrolizumab showed activity in brain metastases in patients with melanoma with an acceptable safety profile and regardless of PD-L1 status.[9] Pembrolizumab is a humanized monoclonal antibody that is directed against human cell surface receptor programmed death 1 (PD-1) with potential immune checkpoint inhibitory and antineoplastic activities. This evidence concerns the gene CD274 and melanoma.